NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Yes I do. IMO, it (even if its minimal) helps to give the FDA cover to approve DCVax-L over any possible BP objections to the use of ECAs. And perhaps there won't even be objections, as the use of ECAs will certainly help to reduce the costs for trials, encourage more patient enrollment, which BPs may very possibly consider beneficial to their own goals as well.

This is only my opinion, of course, but I think it's reasonably supported.